157 related articles for article (PubMed ID: 2941177)
21. Biochemical and pharmacological effects of toremifene metabolites.
Kangas L
Cancer Chemother Pharmacol; 1990; 27(1):8-12. PubMed ID: 2147128
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer.
Taras TL; Wurz GT; DeGregorio MW
J Steroid Biochem Mol Biol; 2001 Jun; 77(4-5):271-9. PubMed ID: 11457665
[TBL] [Abstract][Full Text] [Related]
23. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
24. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors.
Vuorio T; Wärri A; Sandberg M; Alitalo K; Vuorio E
Int J Cancer; 1988 Nov; 42(5):774-9. PubMed ID: 2972630
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3647-51. PubMed ID: 9413217
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology of tamoxifen in laboratory animals.
Jordan VC; Allen KE; Dix CJ
Cancer Treat Rep; 1980; 64(6-7):745-59. PubMed ID: 6775807
[TBL] [Abstract][Full Text] [Related]
27. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
28. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
29. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
30. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
Gundersen S
J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
[TBL] [Abstract][Full Text] [Related]
31. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
32. Development and biochemical pharmacology of toremifene, an antiestrogenic antitumor drug.
Kangas L
Acta Obstet Gynecol Scand; 1991; 70(4-5):399. PubMed ID: 1836089
[No Abstract] [Full Text] [Related]
33. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
34. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
[TBL] [Abstract][Full Text] [Related]
36. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
37. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
38. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
[TBL] [Abstract][Full Text] [Related]
39. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
40. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo.
Howe SR; Gottardis MM; Everitt JI; Walker C
Endocrinology; 1995 Nov; 136(11):4996-5003. PubMed ID: 7588234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
